Department of Nephrology, Huriez Hospital, Lille University Hospital, Lille, France.
INSERM UMR 1246 - SPHERE, Nantes University, Tours University, Nantes, France.
Transplantation. 2021 Feb 1;105(2):396-403. doi: 10.1097/TP.0000000000003209.
In kidney transplantation, dynamic prediction of patient and kidney graft survival (DynPG) may help to promote therapeutic alliance by delivering personalized evidence-based information about long-term graft survival for kidney transplant recipients. The objective of the current study is to externally validate the DynPG.
Based on 6 baseline variables, the DynPG can be updated with any new serum creatinine measure available during the follow-up. From an external validation sample of 1637 kidney recipients with a functioning graft at 1-year posttransplantation from 2 European transplantation centers, we assessed the prognostic performance of the DynPG.
As one can expect from an external validation sample, differences in several recipient, donor, and transplantation characteristics compared with the learning sample were observed. Patients were mainly transplanted from deceased donors (91.6% versus 84.8%; P < 0.01), were less immunized against HLA class I (18.4% versus 32.7%; P < 0.01) and presented less comorbidities (62.2% for hypertension versus 82.7%, P < 0.01; 25.1% for cardiovascular disease versus 33.9%, P < 0.01). Despite these noteworthy differences, the area under the ROC curve varied from 0.70 (95% confidence interval [CI], 0.64-0.76) to 0.76 (95% CI, 0.64-0.88) for prediction times at 1 and 6 years posttransplantation respectively, and calibration plots revealed reasonably accurate predictions.
We validated the prognostic capacities of the DynPG in terms of both discrimination and calibration. Our study showed the robustness of the DynPG for informing both the patient and the physician, and its transportability for a cohort presenting different features than the one used for the DynPG development.
在肾移植中,患者和肾脏移植物生存的动态预测(DynPG)可以通过提供有关肾移植受者长期移植物生存的个性化循证信息来帮助促进治疗联盟。本研究的目的是对 DynPG 进行外部验证。
基于 6 个基线变量,DynPG 可以用随访期间任何新的血清肌酐测量值进行更新。在来自 2 个欧洲移植中心的 1637 名移植后 1 年功能移植物的外部验证样本中,我们评估了 DynPG 的预后性能。
正如外部验证样本所预期的那样,与学习样本相比,观察到受者、供者和移植特征的差异。患者主要来自已故供者(91.6%比 84.8%;P < 0.01),对 HLA Ⅰ类的免疫程度较低(18.4%比 32.7%;P < 0.01),合并症较少(高血压为 62.2%比 82.7%,P < 0.01;心血管疾病为 25.1%比 33.9%,P < 0.01)。尽管存在这些显著差异,但 ROC 曲线下面积在 1 年和 6 年后分别为 0.70(95%置信区间[CI],0.64-0.76)和 0.76(95%CI,0.64-0.88),校准图显示预测结果较为准确。
我们验证了 DynPG 在区分度和校准度方面的预后能力。我们的研究表明,DynPG 可以为患者和医生提供信息,具有稳健性,并且可以在与开发 DynPG 时使用的队列特征不同的队列中进行移植。